8-K: CV Sciences Reports Fiscal Year-End 2023 Results, Achieves Improved Margins and Positive Operating Cash Flow

CV Sciences reported its fiscal year 2023 results, highlighting improved gross margins and positive operating cash flow despite a slight revenue decrease.

Summary

• CV Sciences announced its financial results for the year and quarter ended December 31, 2023.
• The company generated $16.0 million in revenue for fiscal year 2023, a slight decrease from $16.2 million in 2022.
• Gross margin significantly improved to 44.3% for fiscal year 2023, up from 34.2% in 2022.
• The company achieved positive cash flow from operations of $2.3 million in 2023, compared to negative $1.9 million in 2022, which included a $2.5 million employee retention credit.
• Operating expenses were reduced by 20% to $9.9 million for fiscal year 2023, compared to $12.4 million in 2022, excluding the benefit from reversal of accrued payroll taxes.
• Adjusted EBITDA improved by 62% to negative $2.3 million for fiscal year 2023, compared to negative $6.1 million in 2022.
• The company's cash balance at year-end was $1.3 million, compared to $0.6 million at the end of 2022.
• Fourth quarter 2023 revenue was $3.8 million, down from $4.1 million in the third quarter of 2023.
• The company reported an operating income of $3.4 million for fiscal year 2023, compared to an operating loss of $6.8 million in 2022, primarily due to a reversal of accrued payroll tax of $6.2 million, improved gross margins and lower operating expenses.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant improvements in gross margin, cash flow, and operating expenses. However, the slight revenue decrease and negative adjusted EBITDA temper the overall sentiment.

Positives

• Gross margin improved significantly to 44.3% for fiscal year 2023, up from 34.2% in 2022.
• The company generated positive cash flow from operations of $2.3 million in 2023, compared to negative $1.9 million in 2022.
• Operating expenses were reduced by 20% to $9.9 million for fiscal year 2023, compared to $12.4 million in 2022.
• The company's cash balance increased to $1.3 million at year-end, up from $0.6 million at the end of 2022.
• CV Sciences is the top-selling hemp extract brand in the natural product retail sales channel.
• The company successfully launched several new product lines and expanded its pet product offerings.
• The acquisition of Cultured Foods provides a manufacturing and distribution foothold in the EU.

Negatives

• Revenue decreased slightly to $16.0 million for fiscal year 2023, compared to $16.2 million in 2022.
• Fourth quarter 2023 revenue decreased to $3.8 million, compared to $3.9 million in the same prior year period and $4.1 million in the third quarter of 2023.
• The company had a negative adjusted EBITDA of $2.3 million for fiscal year 2023, although this was an improvement from negative $6.1 million in 2022.
• The company had a negative adjusted EBITDA for the fourth quarter of 2023 of $0.5 million, compared to negative adjusted EBITDA of $0.7 million in the fourth quarter of 2022.

Risks

• The company operates in a challenging environment with a consolidating CBD category.
• The company's forward-looking statements are subject to risks, uncertainties, and assumptions that are difficult to predict.
• Actual outcomes and results may differ materially from what is expressed in forward-looking statements.
• The company's revenue decreased slightly year-over-year and sequentially in the fourth quarter of 2023.

Future Outlook

The company will continue to focus on new product development and evaluate merger, sale, acquisition, or other options. They aim to leverage the strengths and assets of the company through M&A as they transition to a global health and wellness company.

Management Comments

• Joseph Dowling, Chief Executive Officer of CV Sciences, stated that they are very pleased with their fiscal year 2023 results.
• He noted that the company's 44.3% gross margin in FY23 is significantly improved from 34.2% in FY22.
• He also stated that their 2023 progress demonstrates their continuous commitment to innovation and cost-efficient execution as they move closer to profitability and positive cash flow.
• Dowling mentioned that as the CBD category consolidates, they have increased their market share in key sales channels, including the natural product retail channel.

Industry Context

The company is operating in a consolidating CBD market, and is focusing on increasing market share in key sales channels. The acquisition of Cultured Foods indicates a move towards diversification and expansion into the plant-based food market, which is a growing trend in the health and wellness industry.

Comparison to Industry Standards

• While specific competitor data is not provided, the company's improved gross margin of 44.3% suggests a positive trend compared to the previous year's 34.2%.
• The positive operating cash flow of $2.3 million is a significant improvement, indicating better financial management.
• The company's claim of being the top-selling hemp extract brand in the natural product retail channel, according to SPINS data, positions them well against competitors in that specific market segment.
• The acquisition of Cultured Foods is a strategic move to diversify and expand into the plant-based food market, which is a growing trend in the health and wellness industry, similar to moves by other companies in the sector.

Legal Proceedings

• The company received preliminary approval of a proposed settlement of a shareholder derivative lawsuit in Q1 2023.

Stakeholder Impact

• Shareholders may view the improved financial performance and strategic acquisitions positively.
• Employees may benefit from the company's improved financial stability and growth.
• Customers may benefit from the company's new product launches and expanded offerings.
• Suppliers may see increased business opportunities with the company's growth.

Next Steps

• The company will host a conference call and webcast to discuss these results.
• The company will continue to focus on new product development.
• The company will continue to evaluate inbound and outbound merger, sale, acquisition or other options.

Key Dates

Keywords

CBD, hemp extract, financial results, gross margin, operating expenses, EBITDA, cash flow, consumer wellness, plant-based foods, nutraceuticals